Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05847179 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin in Werner Syndrome

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoints removed 22 → 20 primary endpoints
See other at-risk trials from PRG Science & Technology Co., Ltd.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified Show 7 more changesShow less
    • Recruitment opened
    • Lead sponsor: PRG Science & Technology Co., Ltd. to PRG Science & Technology Co., Ltd.
    • Start date: Jul 2026 to Oct 2026
    • Study sites: 0 to 1
    • Eligibility criteria expanded, about 26 words
    • Secondary endpoints expanded, about 117 words
    • Study description expanded, about 49 words
  2. Primary completion date: Jan 1, 2026 to Dec 2027
    • Start date: Jan 1, 2025 to Jul 2026
    • Study completion date: Jan 1, 2027 to Dec 2027
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 2, open-label study to A Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin for the Treatment of Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome. There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year.
Trial Details
NCT Number NCT05847179
Lead Sponsor PRG Science & Technology Co., Ltd.
Conditions
(from sponsor)		 Werner Syndrome
Related terms Werner Syndrome
Enrollment 5 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov